Cervical cancer screening and risk factor prevalence by sexual identity: A comparison across three national surveys in the United States
Menée à partir des données de trois enquêtes nationales réalisées entre 2017 et 2021 (taille de l'échantillon analysé : 142 200 personnes au total), cette étude examine le recours au dépistage du cancer du col de l'utérus et les facteurs de risque en fonction de l'identité sexuelle
Objectives : Women identifying as lesbian, gay, bisexual, or queer (LGBQ) have lower cervical cancer screening use and differences in care access. Less known about how differences vary by data sources and within LGBQ subgroups. We evaluated LGBQ disparities in cervical cancer screening use and risk factors across three national surveys in the United States.
Methods : Data were from the 2019 and 2021 National Health Interview Survey, the 2018 and 2020 Behavioral Risk Factor Surveillance Survey, and the 2017–2019 National Survey of Family Growth. We meta-analyzed self-reported cervical cancer screening to estimate pooled relative risks (pRR), comparing those identifying as LGBQ to those identifying as straight/heterosexual. We also evaluated differences in care access and behavioral risk factors by sexual identity.
Results : Despite demographic differences across surveys, all three surveys demonstrated a small reduction in up-to-date cervical cancer screening for LGBQ vs. straight/heterosexual women (pRR = 0.91 [CI 0.89–0.93]). The screening gap was larger for gay/lesbian (pRR: 0.90 [0.85–0.94]) than bisexual women (pRR: 0.94 [0.92–0.97]) and largest at younger ages (pRR age 21–29: 0.89 [CI 0.85–0.93]). LGBQ women reported consistently lower access to care across multiple measures. Risk factors were mixed, including higher smoking rates and higher HPV vaccination coverage for LGBQ women vs. straight.
Discussion : LGBQ women are less likely to be screened for cervical cancer. Closing disparities in care access and identifying feasible and acceptable screening interventions will help reduce these disparities. We must also ensure high-quality data collection to monitor disparities across and within key subgroups.
Preventive Medicine , résumé, 2025